Ryoichi Onozato

Ryoichi Onozato

Auto-generated profile, based on publicly available information

Ryoichi Onozato

Department of General Thoracic Surgery Gunma Prefectural Cancer Center Ota Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Molecular Immunology
Verified
Journal Article
Closed access
TYToshiki Yajima
Toshiki Yajima
KHKouki Hoshino
Kouki Hoshino
RMRyo Muranushi
Ryo Muranushi
AMAkira Mogi
Akira Mogi
RORyoichi Onozato
Ryoichi Onozato
HKHiroyuki Kuwano
Hiroyuki Kuwano

28 August 2021 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
YOYoichi Ohtaki
Yoichi Ohtaki
KKKyoichi Kaira
Kyoichi Kaira
TYToshiki Yajima
Toshiki Yajima
BEBilguun Erkhem‐Ochir
Bilguun Erkhem‐Ochir
OKOsamu Kawashima
Osamu Kawashima
KSKen Shirabe
Ken Shirabe
Objectives: Various drug‐sensitivity markers have been reported to be associated with tumor progression and chemotherapy resistance. Detailed expression profiles of sensitivity markers for cytotoxic chemotherapy in pulmonary large cell neuroendocrine carcinoma (LCNEC) remain unclear. Herein, we aimed to clarify the correlation between the expression of drug‐sensitivity markers and clinicopathological features, prognostic impact, and status of tumor immunity in patients with LCNEC.Methods: We retrospectively analyzed the correlation between clinicopathological features and the expression of drug‐sensitivity‐related markers, including vascular endothelial growth factor 2 (VEGFR2), thymidylate synthase (TS), tubulin beta 3 class III (TUBB3), topoisomerase I (Topo‐I), and Topo‐II in 92 surgically resected LCNEC samples. Furthermore, we examined the prognostic significance of expression of these and their correlation with the immune cell status.Results: Overall, high expression of TS, TUBB3, VEGFR2, Topo‐I, and Topo‐II was detected in 50 (54%), 31 (34%), 23 (25%), 65 (71%), and 36 (39%) samples, respectively. Univariate and multivariate analyses revealed that advanced pathological T and N factors, positive lymphatic permeation, and Topo‐II expression were independent unfavorable prognosticators for recurrence‐free survival, and advanced pathological T and N factors, Topo‐II positive expression, and TS positive expression were independent unfavorable prognosticators for overall survival. In terms of correlation with immune cell status, higher expression of VEGFR2 was closely linked to negative PD‐L1 expression.Conclusions: These findings suggest that elevated Topo‐II and TS expression may contribute to poor outcomes through protumoral biology in patients with LCNEC, and elevated VEGFR2 expression might negatively impact tumor immune reactions in LCNEC.

3 July 2019 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
TKTakayuki Kosaka
Takayuki Kosaka
TYToshiki Yajima
Toshiki Yajima
EYEi Yamaki
Ei Yamaki
SNSeshiru Nakazawa
Seshiru Nakazawa
KTKenji Tomizawa
Kenji Tomizawa
KSKen Shirabe
Ken Shirabe
Anaplastic lymphoma kinase (ALK) gene rearrangements are identified in approximately 5% of patients with non‑small cell lung cancer (NSCLC). Despite initial dramatic responses to ALK inhibitors, the majority of patients relapse within 1 year, owing to the development of resistance. Herein we present a case of variant type 2 ALK‑rearranged lung adenocarcinoma recurrence with multiple lung metastasis that maintained complete response over 5 years with crizotinib, which is the first approved ALK inhibitor. The efficacy of crizotinib may vary among ALK fusion variants and thus, variant type may represent an important factor in guiding the treatment strategy for ALK‑rearranged lung adenocarcinoma.